Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.

NCT00337662 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00337662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00337662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2006
Completion date
December 31, 2007
Enrollment
628 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia, schizophreniform disorder